Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

about

A systems approach to designing effective clinical trials using simulations.Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.The Creating an Optimal Warfarin Nomogram (CROWN) Study.

P2860

Q37106741-C2849E97-FF88-45AB-BCC8-761B24A3487A Q46008192-E6A39529-C5B1-411B-809F-726F87D295DB Q51489676-F3DCB974-EB32-41DA-9949-4EA5D7C4D28E

P2860

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

Item

http://www.wikidata.org/entity/Q38274487

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Pharmacogenomic trial design: ...... ugh clinical trial simulation.

@en

type

Item

label

Pharmacogenomic trial design: ...... ugh clinical trial simulation.

@en

prefLabel

Pharmacogenomic trial design: ...... ugh clinical trial simulation.

@en

P1476

Pharmacogenomic trial design: ...... ough clinical trial simulation

@en

P2093

Ann K Wittkowsky

http://www.w3.org/2001/XMLSchema#string

David H Salinger

http://www.w3.org/2001/XMLSchema#string

David L Veenstra

http://www.w3.org/2001/XMLSchema#string

Kenneth Thummel

http://www.w3.org/2001/XMLSchema#string

Paolo Vicini

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients.

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

P304

965-971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E3283333B80

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Danny D Shen

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19881396

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

3164437

http://www.w3.org/2001/XMLSchema#string

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

about

P2860

P2860

Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932